Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-25-095008
Filing Date
2025-04-25
Accepted
2025-04-25 07:54:01
Documents
22
Period of Report
2025-06-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A d908937ddef14a.htm   iXBRL DEF 14A 1087758
6 GRAPHIC g908937g22k01.jpg GRAPHIC 198922
7 GRAPHIC g908937g22k02.jpg GRAPHIC 155370
8 GRAPHIC g908937g22k03.jpg GRAPHIC 142391
9 GRAPHIC g908937g22k04.jpg GRAPHIC 232067
10 GRAPHIC g908937g22k05.jpg GRAPHIC 269734
11 GRAPHIC g908937g79t90.jpg GRAPHIC 55364
  Complete submission text file 0001193125-25-095008.txt   4378505

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20241231.xsd EX-101.SCH 4064
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vrdn-20241231_def.xml EX-101.DEF 3566
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20241231_lab.xml EX-101.LAB 4005
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20241231_pre.xml EX-101.PRE 3291
24 EXTRACTED XBRL INSTANCE DOCUMENT d908937ddef14a_htm.xml XML 116461
Mailing Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453
Business Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36483 | Film No.: 25870018
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)